Shield Therapeutics PLC (STX) Now Covered by FinnCap
Research analysts at FinnCap initiated coverage on shares of Shield Therapeutics PLC (LON:STX) in a research note issued on Thursday. The brokerage set a “buy” rating and a GBX 270 ($3.49) price target on the stock. FinnCap’s price target suggests a potential upside of 71.43% from the company’s current price.
STX has been the subject of several other research reports. Liberum Capital reiterated a “buy” rating and set a GBX 245 ($3.16) price target on shares of Shield Therapeutics PLC in a research note on Thursday, June 22nd. Peel Hunt reiterated a “buy” rating and set a GBX 220 ($2.84) price target on shares of Shield Therapeutics PLC in a research note on Thursday, July 6th.
Shield Therapeutics PLC (STX) remained flat at GBX 157.50 during midday trading on Thursday. The company’s stock had a trading volume of 2,500 shares. Shield Therapeutics PLC has a 52-week low of GBX 149.50 and a 52-week high of GBX 177.00. The firm’s market capitalization is GBX 183.37 million. The company has a 50 day moving average of GBX 157.50 and a 200-day moving average of GBX 163.49.
TRADEMARK VIOLATION WARNING: This story was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this story on another website, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The original version of this story can be read at https://www.americanbankingnews.com/2017/09/10/shield-therapeutics-plc-stx-now-covered-by-finncap.html.
Shield Therapeutics PLC Company Profile
Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals. The Company’s product, Feraccru, is an oral treatment for iron deficiency anemia (IDA) in patients for whom intravenous iron or blood transfusions is needed.
Receive News & Ratings for Shield Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.